Présentation de l'entreprise
Kiora Pharmaceuticals, Inc. operates as a clinical-stage specialty pharmaceutical entity dedicated to the research and development of therapies specifically designed for ophthalmic diseases. The company functions within the healthcare sector and the biotechnology industry, positioning itself to leverage scientific innovation for the treatment of visual conditions. Its financial scale is characterized by a market capitalization of $11.30M, while annual revenue data is currently unavailable and the number of employees is not disclosed. These valuation metrics indicate that the company remains in a pre-commercial or early-stage phase of its lifecycle, where capital is primarily allocated toward advancing clinical trials rather than generating substantial sales revenue. The absence of reported revenue figures alongside a market cap under $12 million suggests the firm is still evaluating the commercial potential of its pipeline assets, particularly its lead product KIO-301, before establishing a significant market footprint.
Santé financière
The company reports a net income of $-10,835,154 over the trailing twelve months, while EBITDA stands at $-9,434,446, indicating significant operational expenditures that exceed current revenue generation. The gap between revenue and net income reveals a cost structure heavily weighted toward research and development expenses typical for a clinical-stage biotechnology firm, where revenue is either non-existent or negligible in the trailing period. Free cash flow for the period was $-9,187,735, which signifies that the company is burning cash to fund its operations and clinical programs rather than generating surplus liquidity for immediate distribution. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a financial state where costs fully consume revenue or where no revenue has been recognized in the trailing twelve months. On the liability side, the company holds $17.09M in cash against $368,259 in debt, resulting in a debt-to-equity ratio of 2.28, which indicates a leveraged balance sheet structure despite the minimal absolute debt burden. The current ratio of 5.99 demonstrates robust short-term liquidity, suggesting the firm possesses ample current assets to cover its short-term obligations without immediate distress. However, the return on equity of -51.7% and return on assets of -19.5% reveal that management has not yet achieved profitability, as the company's capital base is currently generating negative returns due to ongoing clinical trial costs and lack of commercial income.
Évaluation de la valorisation
Trailing P/E and forward P/E ratios are effectively negative or undefined for valuation purposes given the lack of positive earnings, with the forward P/E specifically listed as -1.28, implying that the market prices the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio is 0.67, indicating that the market values the company at a discount relative to its book value, a common characteristic for biotechnology firms with significant intangible assets like intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA provide further context, where the EV/EBITDA stands at 0.57, suggesting a low enterprise value multiple relative to earnings before interest, taxes, depreciation, and amortization, though the negative earnings complicate this comparison. The 52-week trading range spans from a low of $1.76 to a high of $4.18, and the current price sits within this band, reflecting the volatility typical of small-cap clinical-stage companies. The beta of -0.77 is anomalous for a single stock, suggesting an inverse correlation with the broader market or a specific data anomaly that increases price volatility relative to the market index.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A due to the absence of positive revenue and earnings in the trailing twelve months, which precludes a calculation of year-over-year growth percentages. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm reinvests all available resources, including its cash reserves, into advancing its clinical pipeline and operational infrastructure. The lack of a dividend payout is consistent with the capital-intensive nature of biotechnology, where cash is required to fund Phase 2 clinical trials for lead products rather than distributed to shareholders. Overall, the growth and income profile is defined by a reliance on future clinical success and regulatory approval to transition from a cash-burning stage to a revenue-generating entity, with no current income streams or dividend distributions to support shareholder returns.